MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Companies: Merger Partners_(M&A)
Q32 Bio Inc. (NASDAQ: QTTB)*
Organization & Developments: Q32 Bio
Parents
Q32 Bio Inc. (NASDAQ: QTTB)*
Children
*2024: Q32 Bio to focus on advancement of bempikibart (ADX-914) in ongoing atopic dermatitis (AD) and alopecia areata (AA) Phase 2 clinical trials and commencement of ADX-097 Phase 2 renal basket clinical trial in patients with complement disorders
*Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases.
*Q32 Bio is a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases.
2024: Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
2026: Q32 Bio: Bempikibart's Progress Keeps Me Bullish
2026: Q32 Bio: The Efficacy Is Modest, The Valuation Is Not (NASDAQ:QTTB)
Jumps
Finance & Acquisitions: Q32 Bio
Key People: Q32 Bio